Fifth, to address the absence of experimental validation, we plan to incorporate experimental validation through CRISPR-based protein knockdowns of SFTPB and CEACAM5 in NSCLC cell lines in our future work. Here, SFTPB is linked to non-small cell lung carcinoma.